Bioversys 2020-04: Virulence and Secondary Infection Markers in the Murine Dermonecrosis Model with S. aureus and Efficacy of Anti-Virulence Compounds

Project Details

StatusFinished
Effective start/end date4/06/20 → 3/06/21

Funding

  • BioVersys AG: $73,543.98